Skip to main content


2008 News Releases

Webcast ImageWebcast
Emergent BioSolutions Inc. at RBC Capital Markets 2019 Healthcare Conference  (Replay)
05/21/19 at 3:05 p.m. ET
Webcast ImageWebcast
Emergent BioSolutions Inc. 2019 Annual Shareholder Meeting (Replay)
05/23/19 at 9:00 a.m. ET
Keyword Search
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
12/19/08Emergent BioSolutions Receives FDA Approval for BioThrax Supplemental Biologics License Application Printer Friendly Version
12/08/08Emergent BioSolutions to Webcast Presentation at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009 Printer Friendly Version
11/18/08Emergent BioSolutions to Webcast Presentation at the 6th Annual Southwestern Showcase Investor Conference on November 20, 2008 Printer Friendly Version
11/12/08Emergent BioSolutions Files Universal Shelf Registration Statement Printer Friendly Version
11/06/08Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2008 Printer Friendly Version
10/31/08Emergent BioSolutions to Webcast Presentation at the Rodman & Renshaw Annual Global Investment Conference on November 12, 2008 Printer Friendly Version
10/16/08Emergent BioSolutions to Release Third Quarter 2008 Financial Results and Conduct a Conference Call on November 6, 2008 Printer Friendly Version
10/09/08U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax(R) and Anthrax Immune Globulin under Prep Act Printer Friendly Version
10/01/08U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million Printer Friendly Version
09/26/08Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine Printer Friendly Version
09/12/08Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range Printer Friendly Version
09/03/08Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody Printer Friendly Version
08/07/08Emergent BioSolutions Reports Financial Results for Second Quarter 2008 Printer Friendly Version
08/05/08Emergent BioSolutions to Present at the BMO Capital Markets Focus on Healthcare Conference on August 6, 2008 Printer Friendly Version
07/31/08Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine Printer Friendly Version
07/29/08Statement by Emergent BioSolutions in Response to Attempt by Protein Sciences Corporation to Terminate Asset Purchase Transaction Printer Friendly Version
07/25/08Emergent BioSolutions to Release Second Quarter 2008 Financial Results and Conduct a Conference Call on August 7, 2008 Printer Friendly Version
07/24/08Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company's Recombinant Botulinum Vaccine (rBOT) and Next Generation Anthrax Vaccine (NGAV) Candidates Printer Friendly Version
07/23/08Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust and Aeras Global TB Vaccine Foundation Printer Friendly Version
07/09/08Emergent BioSolutions Initiates Lawsuit Against Protein Sciences and Its Senior Management Regarding Delayed Asset Acquisition Printer Friendly Version
06/05/08Emergent BioSolutions and the European Corporate Security Association (ECSA) Sponsor a Conference on Bioterrorism Printer Friendly Version
06/05/08Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate Printer Friendly Version
06/04/08Emergent BioSolutions to Webcast Presentation at the Jefferies and Company 2nd Annual Healthcare Conference on June 25, 2008 Printer Friendly Version
05/27/08Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), and Related Novel Platform Technology Printer Friendly Version
05/07/08Emergent BioSolutions Reports Financial Results for First Quarter 2008 Printer Friendly Version
05/05/08Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate and Technology Printer Friendly Version
04/10/08Emergent BioSolutions to Release First Quarter 2008 Financial Results and Conduct a Conference Call On May 7, 2008 Printer Friendly Version
04/08/08Emergent BioSolutions to Hold Annual Meeting of Stockholders Wednesday, May 21, 2008 at 10:00 am Eastern Printer Friendly Version
03/10/08Emergent BioSolutions to Present at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008 Printer Friendly Version
03/07/08Emergent BioSolutions Reports Financial Results for 2007 Printer Friendly Version
03/06/08Emergent BioSolutions Acquires Monoclonal Anthrax Product Candidate Printer Friendly Version
03/03/08Emergent BioSolutions Appoints Dr. W. James Jackson as Chief Scientific Officer Printer Friendly Version
02/25/08Emergent BioSolutions to Release Full Year 2007 Financial Results and Conduct a Conference Call on March 7, 2008 Printer Friendly Version
02/07/08Emergent BioSolutions to Present at BIO CEO & Investor Conference on February 11, 2008 Printer Friendly Version
01/24/08Emergent BioSolutions and Ninebio Sdn. Bhd. Announce Joint Venture in Malaysia Printer Friendly Version
01/09/08Safety Monitoring Committee Recommends That Emergent BioSolutions Continue Its Hepatitis B Immunotherapy Phase II Trial Printer Friendly Version
01/08/08Emergent BioSolutions Announces That the Final Phase II Clinical Study Results for Typhoid Vaccine Reaffirms Clinical Endpoints Met; Immune Response Seen in 97% of Treated Subjects Printer Friendly Version
01/07/08Emergent BioSolutions Announces Better-Than-Expected Preliminary 2007 Financial Results and Provides 2008 Guidance Printer Friendly Version